Overall, it seems that FMT treatment in AD mouse models has the potential to reverse microbiota alterations, improve cognition and synaptic plasticity, decrease Aβ and tau pathology and to reduce neuroinflammation (171, 173). The gene discussed is MAPT; the disease is Alzheimer disease.